Samantha Semenkow
Stock Analyst at Citi
(0.76)
# 3,823
Out of 4,371 analysts
204
Total ratings
41.7%
Success rate
-2.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SABS SAB Biotherapeutics | Initiated Coverage: Buy | $11 | $3.47 | +217.00% | 1 | May 22, 2026 | |
| ROIV Roivant Sciences | Reiterated: Buy | $35 → $42 | $29.53 | +42.23% | 5 | May 21, 2026 | |
| NKTR Nektar Therapeutics | Maintained: Buy | $151 | $59.31 | +154.59% | 9 | May 13, 2026 | |
| BEAM Beam Therapeutics | Maintained: Buy | $68 | $32.84 | +107.06% | 15 | May 13, 2026 | |
| ARGX argenx SE | Reiterated: Buy | $1,152 | $842.27 | +36.77% | 19 | May 12, 2026 | |
| CPRX Catalyst Pharmaceuticals | Downgraded: Hold | $35 → $32 | $31.29 | +0.67% | 12 | May 7, 2026 | |
| SYRE Spyre Therapeutics | Rated: Buy | $64 → $97 | $78.48 | +23.60% | 3 | May 6, 2026 | |
| WVE Wave Life Sciences | Rated: Buy | $30 → $24 | $6.09 | +294.09% | 4 | May 1, 2026 | |
| ALLO Allogene Therapeutics | Rated: Buy | $4 | $2.04 | +96.08% | 6 | Apr 9, 2026 | |
| BHVN Biohaven | Maintained: Buy | $14 → $17 | $11.40 | +49.12% | 6 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $46 | $28.79 | +59.78% | 4 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $3.62 | +203.87% | 6 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $3.29 | +325.53% | 17 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $136 → $142 | $87.61 | +62.08% | 2 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $6 | $18.72 | -67.95% | 9 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $100 | $39.06 | +156.02% | 5 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $52 | $17.02 | +205.52% | 9 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $2.96 | +305.41% | 14 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $33 | $14.43 | +128.69% | 1 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $5 → $4.25 | $3.47 | +22.48% | 8 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $3.51 | +184.90% | 11 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $58 → $57 | $32.67 | +74.47% | 15 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $5 | $2.99 | n/a | 9 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 → $4 | $16.60 | n/a | 8 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.7 → $0.75 | $0.00001 | n/a | 3 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $130 | $17.34 | n/a | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 → $7 | $5.40 | n/a | 2 | Jul 21, 2021 |
SAB Biotherapeutics
May 22, 2026
Initiated Coverage: Buy
Price Target: $11
Current: $3.47
Upside: +217.00%
Roivant Sciences
May 21, 2026
Reiterated: Buy
Price Target: $35 → $42
Current: $29.53
Upside: +42.23%
Nektar Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $151
Current: $59.31
Upside: +154.59%
Beam Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $68
Current: $32.84
Upside: +107.06%
argenx SE
May 12, 2026
Reiterated: Buy
Price Target: $1,152
Current: $842.27
Upside: +36.77%
Catalyst Pharmaceuticals
May 7, 2026
Downgraded: Hold
Price Target: $35 → $32
Current: $31.29
Upside: +0.67%
Spyre Therapeutics
May 6, 2026
Rated: Buy
Price Target: $64 → $97
Current: $78.48
Upside: +23.60%
Wave Life Sciences
May 1, 2026
Rated: Buy
Price Target: $30 → $24
Current: $6.09
Upside: +294.09%
Allogene Therapeutics
Apr 9, 2026
Rated: Buy
Price Target: $4
Current: $2.04
Upside: +96.08%
Biohaven
Apr 2, 2026
Maintained: Buy
Price Target: $14 → $17
Current: $11.40
Upside: +49.12%
Mar 31, 2026
Reiterated: Buy
Price Target: $46
Current: $28.79
Upside: +59.78%
Mar 23, 2026
Reiterated: Buy
Price Target: $11
Current: $3.62
Upside: +203.87%
Mar 20, 2026
Reiterated: Buy
Price Target: $14
Current: $3.29
Upside: +325.53%
Mar 20, 2026
Rated: Buy
Price Target: $136 → $142
Current: $87.61
Upside: +62.08%
Mar 20, 2026
Maintained: Sell
Price Target: $6
Current: $18.72
Upside: -67.95%
Mar 16, 2026
Reiterated: Buy
Price Target: $100
Current: $39.06
Upside: +156.02%
Mar 10, 2026
Maintained: Buy
Price Target: $15 → $52
Current: $17.02
Upside: +205.52%
Mar 4, 2026
Maintained: Buy
Price Target: $12
Current: $2.96
Upside: +305.41%
Feb 18, 2026
Initiated Coverage: Buy
Price Target: $33
Current: $14.43
Upside: +128.69%
Nov 11, 2025
Maintained: Hold
Price Target: $5 → $4.25
Current: $3.47
Upside: +22.48%
Oct 10, 2025
Reiterated: Buy
Price Target: $10
Current: $3.51
Upside: +184.90%
Aug 12, 2025
Maintained: Buy
Price Target: $58 → $57
Current: $32.67
Upside: +74.47%
Mar 6, 2025
Maintained: Buy
Price Target: $15 → $5
Current: $2.99
Upside: n/a
Jun 3, 2024
Initiated Coverage: Buy
Price Target: $6 → $4
Current: $16.60
Upside: n/a
May 18, 2023
Maintained: Hold
Price Target: $1.7 → $0.75
Current: $0.00001
Upside: n/a
May 11, 2023
Rated: Buy
Price Target: $130
Current: $17.34
Upside: n/a
Jul 21, 2021
Maintained: Buy
Price Target: $16 → $7
Current: $5.40
Upside: n/a